EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Hermine I Brunner iD, Jordi Antón iD, Inmaculada Calvo-Penadés, Richard Dimelow, Gerd Horneff iD, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik iD, Kirsten Minden, Masaaki Mori, Josephine Ocran-Appiah, Christel Wilkinson und 3 weitere

Arthritis Care & Research · 2026

DOI: 10.1002/acr.25700 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Hermine I Brunner und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy.

Methods

This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier: NCT04179032) used three‐weight‐band subcutaneous dosing of belimumab 200 mg every week (qw) for pediatric patients weighing ≥50 kg, every 10 days for pediatric patients weighing 30 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsHumansChildFemaleMaleAdolescentInjections, SubcutaneousTreatment Outcome

Substanzen

belimumabAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
  • Hospital Universitario y Politécnico La Fe, València, Spain.
  • GSK, Stevenage, United Kingdom.
  • Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany.
  • University Hospital of Cologne, Cologne, Germany.

ORCID-Profile: Hermine I Brunner, Jordi Antón, Gerd Horneff, Andre van Maurik, Yuichi Yamasaki

Förderung

  • GSK

Zitieren

APA

Brunner, H. I., Antón, J., Calvo-Penadés, I., Dimelow, R., Horneff, G., Kamphuis, S., Marino, R., van Maurik, A., Minden, K., Mori, M., Ocran-Appiah, J., Wilkinson, C., Yamasaki, Y., Assudani, D., & Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators (2026). Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial. Arthritis Care & Research. https://doi.org/10.1002/acr.25700

Vancouver

Brunner HI, Antón J, Calvo-Penadés I, Dimelow R, Horneff G, Kamphuis S, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial. Arthritis Care & Research. 2026. doi:10.1002/acr.25700

BibTeX
@article{Brunner2026,
  author = {Brunner, Hermine I and Antón, Jordi and Calvo-Penadés, Inmaculada and Dimelow, Richard and Horneff, Gerd and Kamphuis, Sylvia and Marino, Rebecca and van Maurik, Andre and Minden, Kirsten and Mori, Masaaki and Ocran-Appiah, Josephine and Wilkinson, Christel and Yamasaki, Yuichi and Assudani, Deepak and Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators, Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators},
  title = {Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial},
  journal = {Arthritis Care & Research},
  year = {2026},
  doi = {10.1002/acr.25700}
}
Kostenlos starten →